An interventional study of Lactoferrin and DHA and Placebo in Fetal Growth Retardation and Intrauterine Growth Restriction, sponsored by Institut d'Investigacions Biomèdiques August Pi i Sunyer. Recruiting at 6 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Institut d'Investigacions Biomèdiques August Pi i Sunyer · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Fetal Growth Retardation with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Fetal Growth Retardation · Spain.
Among the 18 studies in Fetal Growth Retardation with a site in Spain, this one is the 7th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 with no phase, and was the 13th registered.
262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.
Browse Fetal Growth Retardation studies →7 of the 18 studies in Fetal Growth Retardation with a site in Spain are open now. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 18+ · Women only
Aristotle University Of Thessaloniki · Sites in Spain, Bulgaria, Greece
Ages 18+ · Women only · Healthy volunteers
Leiden University Medical Center · Sites in Spain, United States, Belgium and 3 more countries
Ages 18–50
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain, Belgium, Colombia and 6 more countries
Ages 18+ · Women only · Healthy volunteers
Boston Children's Hospital · Sites in Spain, United States
Ages 18–45 · Women only · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 48 Fetal Growth Retardation studies recruiting now, 24 (50%) set no upper age limit and 21 (44%) stop at 75 or younger; 16 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 304 is above the median of 150 across 110 interventional studies indexed under Fetal Growth Retardation.
Median enrollment 340 across the 11 interventional studies, 274 across the 7 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 18 has an industry lead sponsor. The 10 most frequent:
Institut d'Investigacions Biomèdiques August Pi i Sunyer is the lead sponsor of 9 studies on the registry; 4 are open to participants now.
Institut d'Investigacions Biomèdiques August Pi i Sunyer has 1 study filed under Fetal Growth Retardation — fewer than ten, so there is no comparison to draw.
3 of the studies in Fetal Growth Retardation with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04766866Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauSFlt1/PlGF and Planned Delivery to Prevent Preeclampsia At Term. | 2026-12-31 |
| NCT02297724Boston Children's HospitalMRI Assessment of Placental Health | 2027-09 |
| NCT07098975Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauStatin Intervention for Severe Early-Onset Placental Insufficiency. (STATIN-PRE Trial) | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Fetal Growth Retardation with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Singleton pregnancies being diagnosed of fetal growth restriction from 24 to 32.6 weeks of gestation will be randomized to two equally sized groups: maternal oral supplementation with Lactoferrin and DHA (Docosahexaenoic acid) or placebo.
Randomized controlled trial among pregnant women that have been diagnosed of fetal growth restriction. These women will be randomized in order to evaluate the impact of maternal supplementation with Lactoferrin and DHA on the neurodevelopment outcome of their babies.
Main hypothesis: a prenatal intervention based on maternal supplementation with Lactoferrin and DHA improves neurodevelopment in fetal growth restriction.
Secondary hypothesis are that a prenatal intervention based on maternal supplementation with Lactoferrin and DHA in fetal growth restriction improves fetal growth and improves perinatal morbidity and mortality.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily
Dietary Supplement: Lactoferrin and DHA
Product with the same physical appearance and taste as the main intervention but without therapeutic effect
Other: Placebo
Drug page: LactoferrinStudies of LactoferrinLactoferrin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily
Product with the same physical appearance and taste as the main intervention but without therapeutic effect
Bayley III scale at 24 months of age
Bayley III scale is and individually administered instrument that assesses infant development across five domains, including cognitive, language and motor competencies. Parent reported questionnaires are incorporated to assess social-emotional and adaptative behaviors.
Time frame: 24 months of corrected postnatal age
Cortical development
Assessed by fetal brain magnetic resonance imaging.
Time frame: 34 weeks of gestation
Fetal brain volume
Assessed by fetal brain magnetic resonance imaging.
Time frame: 34 weeks of gestation
Corpus callosum area
Assessed by fetal neurosonography.
Time frame: Enrolment, 32 and 36 weeks of gestation
Neonatal weight
Birth weight
Time frame: Delivery
Perinatal morbidity and mortality
Development of one of the following conditions: pregnancy complications, perinatal mortality, metabolic acidosis and major neonatal morbidity.
Time frame: Perinatal period: period ranging from 32 weeks of gestation (154 days) to the end of the first 4 weeks of neonatal life (28 days)
Postnatal neurodevelopmental assessment
Neurodevelopmental assessment using the Bayley III scale at 6 and 24 months of corrected postnatal age, as described in the primary outcome. A complementary neurodevelopmental assessment will be carried out in collaboration with the Speech Acquisition and Perception Groups of the University Pompeu Fabra Barcelona.
Time frame: Between 4 and 24 months of corrected postnatal age
Occurrence of adverse effects
Record of side effects that may appear. Since intervention is usually well tolerated, we do not expect major side effects.
Time frame: Through intervention (supplementation) completion, from enrolment to delivery
PDFs hosted by the registry, ClinicalTrials.gov.
Started Jan 2023 (actual). Primary completion is estimated for Sep 2028, 68 months after the start.
Of 39 non-industry interventional studies with no phase under Fetal Growth Retardation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 52. This study's planned 68 months is above that.
Counting every sponsor, half of 40 studies reached it within 35 months; a quarter within 18 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Sep 2026 → Sep 2028 and completion Dec 2026 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lactoferrin
Institut d'Investigacions Biomèdiques August Pi i Sunyer